SCHEMBL208579

SCHEMBL208579

CNC(N)=O.O=C(O)c1ccc(-c2cc(Cl)c(C[C@@H]3CCN([C@H]4CC[C@H](O)CC4)C3=O)c(Cl)c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.35
RXRA P19793 2/20 0.32
RXRB P28702 2/20 0.32
LTA4H P09960 1/20 0.31
CFB P00751 1/20 0.31
HSP90AA1 P07900 1/20 0.31
SSTR5 P35346 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
PDE4D Q08499 2/20 0.30
DCK P27707 1/20 0.30
PDE5A O76074 1/20 0.30
PDE1A P54750 1/20 0.30
PDE1B Q01064 1/20 0.30
PDE7A Q13946 1/20 0.30
PDE1C Q14123 1/20 0.30
PDE3A Q14432 1/20 0.30
CMA1 P23946 2/20 0.30
PLAU P00749 1/20 0.30
ADRB3 P13945 1/20 0.30
PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210000 0.94 HSD11B1 (0.35) HSD11B1RXRARXRBLTA4HCFB
SCHEMBL209205 0.91 HSD11B1 (0.33) HSD11B1RXRARXRBLTA4HCMA1
SCHEMBL208232 0.86 CMA1 (0.32) HSD11B1PDE4DCMA1ADRB3PDE4A
SCHEMBL210001 0.84 PDE4B (0.37) HSD11B1HRH3PDE4B
SCHEMBL209999 0.84 PDE4B (0.37) HSD11B1HRH3PDE4B
SCHEMBL208578 0.84 PDE4B (0.35) HSD11B1PDE4B
SCHEMBL208580 0.84 PDE4B (0.35) HSD11B1PDE4B
SCHEMBL209306 0.84 HSD11B1 (0.51) HSD11B1RXRARXRBCFBSSTR5
SCHEMBL208451 0.83 HSD11B1 (0.37) HSD11B1RXRARXRBSSTR5PDE4D
SCHEMBL208450 0.83 HSD11B1 (0.37) HSD11B1RXRARXRBSSTR5PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US claimed
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885RXRA 3741/4885RXRB 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.